Genomic profiling of non-small cell lung cancer in the community setting

Published in conjunction with the 2016 ASCO Annual Meeting

Genotyping in patients with advanced NSCLC may identify mutations amenable to targeted therapy. We identified in a 2010-2014 community series a 60% testing rate for EGFR/ALK among stage IV patients (Gutierrez ASCO 2015; e19113). 2014 guidelines added 5 additional targets for testing.

Authors: Martin Gutierrez, Kelly Choi, Richard Burnham Lanman, Stan M Skrzypczak, Ruth Pe Benito, Victoria DeVincenzo, Yvonne Owusu-Sarpong, Courtney Anderson, Dhakshila Paramanathan, Kathyrn Tanenbaum, Matthew Love, Eric V Schultz, Andrew Pecora, Stuart L. Goldberg; John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, NJ; COTA, New York, NY; Guardant Health Inc., Redwood City, CA

Thank you signing up!
Oops! Something went wrong while submitting the form

Adherence to the 2013 CAP/IASLC/AMP Molecular Testing Guidelines in Non-Small Cell Lung Cancer in the Community Setting: Opportunities for Improvement

The 2013 CAP/IASLC/AMP joint guidelines call for EGFR/ALK testing in all patients (pts) with stage IV NSCLC with adenocarcinoma components. In 2014 the NCCN guidelines added emerging actionable targets. The adoption rate of guidelines in community practice has not been fully explored for these two sets of guideline endorsements.
March 16, 2017
Research Abstract

Utilization and clinical impact of genomic profiling for EGFR and ALK in nonsquamous non-small cell lung cancer (NSCLC) in the community setting

Targeted therapies may increase survival in metastatic NSCLC. Thus, genomic profiling is recommended to aid treatment selection. Utilization & impact of testing in community (non-research) settings is underexplored.
March 16, 2017
Research Abstract

Prospective Assessment of the Value of Genomic Profiling in Metastatic Lung Cancer

This prospective observational study is designed to reveal genomic profiling patterns and the influence of testing on clinical and economic outcomes among patients with advanced lung cancer in real world settings
March 16, 2017
Research Abstract

Real-World Comparative Effectiveness of Albumin-Bound Paclitaxel Plus Carboplatin Versus Solvent-Based Paclitaxel Plus Carboplatin

In a subset analysis of a multinational phase III randomized clinical trial, weekly albumin-bound paclitaxel + carboplatin demonstrated a higher response rate than solvent-based paclitaxel + carboplatin every 3 weeks, with less grade ≥3 neuropathy and arthralgia, but more thrombocytopenia and anemia in patients with advanced squamous cell carcinoma non–small cell lung cancer. NCCN Guidelines support the use of nab-P/C, but there is limited published experience with this combination in real-world settings.
March 14, 2017
Research Abstract